PRECEDE-HF Clinical Trial To Evaluate Ability Of Cardiac Trend Data To Prevent Heart Failure Hospitalizations
Oct 11th 2007Drug InformationCardiovascular
Medtronic, Inc. (NYSE: MDT) announced that it has begun enrolling in the PRECEDE-HF clinical trial that will evaluate Medtronic’s proprietary Cardiac CompassŪ and OptiVolŪ Fluid Status Monitoring features to determine whether cardiac trend data may help physicians prevent heart failure hospitalizations. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
